Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In the report of the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial, Dr Lespérance and colleagues1 conclude that the first step in the treatment of such patients with major depression and coronary artery disease should begin with citalopram or sertraline. While this conclusion seems well founded based on the data from CREATE and those of prior trials, there are some questions related to the generalizability of their findings that must be addressed.
Ziegelstein RC. Treatment of Depression in Patients With Coronary Artery Disease. JAMA. 2007;297(17):1878–1880. doi:10.1001/jama.297.17.1878-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: